Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JY5S
|
|||
| Former ID |
DAP001109
|
|||
| Drug Name |
Methantheline
|
|||
| Synonyms |
Mantheline; Methanide; Methanthelinium; Methanthelinum; Banthine bromide; Gastrin I; Methanthine bromide; Gastrin-1 Human; Diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; N,N-Diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastritis [ICD-11: DA42] | Approved | [1] | |
| Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K55-K64, K58] | Approved | [1] | ||
| Pancreatitis [ICD-11: DC31-DC34] | Approved | [1] | ||
| Peptic ulcer [ICD-11: DA61] | Approved | [1] | ||
| Therapeutic Class |
Anticholinergic Agents
|
|||
| Company |
Shire Development Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26NO3+
|
|||
| Canonical SMILES |
CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13
|
|||
| InChI |
1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1
|
|||
| InChIKey |
GZHFODJQISUKAY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 5818-17-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10051, 5065188, 7849622, 7979926, 8152569, 11112123, 11467094, 11468214, 11486702, 14802373, 29223206, 46505807, 47365391, 47440448, 48110636, 48185161, 49699275, 57322139, 79115168, 85209433, 85787544, 103828388, 104305419, 117579898, 123099364, 124881918, 128027980, 134338354, 134987914, 137004191, 179225196, 198968480, 223440306, 223509410, 226457267
|
|||
| ChEBI ID |
CHEBI:6817
|
|||
| SuperDrug ATC ID |
A03AB07
|
|||
| SuperDrug CAS ID |
cas=005818177
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Methantheline bromide (adjusted p-values: 8.71E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor M5 (CHRM5) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Muscarinic acetylcholine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.